Fluorine-18-ML-10

Drug Profile

Fluorine-18-ML-10

Alternative Names: [18F]-ML-10; ApoSense-PET; F-18-ML-10; ML-10

Latest Information Update: 16 Mar 2016

Price : $50

At a glance

  • Originator Aposense
  • Developer Aposense; GlaxoSmithKline
  • Class Diagnostic agents; Imaging agents; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Brain metastases; Head and neck cancer; Lung cancer; Non-Hodgkin's lymphoma; Solid tumours; Stroke

Most Recent Events

  • 16 Mar 2016 Suspended - Phase-II for Brain metastases (Diagnosis) in Israel, USA (IV)
  • 16 Mar 2016 Suspended - Phase-II for Solid tumours, Lung cancer and Head and neck cancer (Diagnosis) in USA (IV)
  • 04 Jun 2015 GlaxoSmithKline terminates a phase II trial in Solid tumours (Diagnosis) in United Kingdom due to non-significant results (NCT01428440) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top